Growing Incidence of HIV to Propel HIV Associated Lipodystrophy Syndrome Market

San Francisco, California, 23th November 2018: HIV-associated lipodystrophy is clinically characterized by body fat changes, including subcutaneous fat loss (lipoatrophy) with or without truncal fat accumulation (lipohypertrophy). The presence of lipodystrophy appears to accelerate the failure of insulin secretion. A recent market research study, titled as “HIV Associated Lipodystrophy Syndrome Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017 – 2025,” talks about the general market scenario, its drivers, trends, and possible restraints. The report additionally delves into the competitive landscape of the global HIV associated lipodystrophy syndrome market, elucidating on the strategies to be adopted by vendors in order to gain market traction over the forecast period of 2017 to 2025.

Get Sample Copy of this Report @ 

https://www.tmrresearch.com/sample/sample?flag=B&rep_id=96

The surge in incidence of HIV is required to drive development of the HIV-associated lipodystrophy market as a large portion of the general population experiencing HIV additionally experience the ill effects of HIV-associated lipodystrophy. As indicated by an article distributed in National Center for Biotechnology Information (NCBI) in 2014, predominance of lipodystrophy in individuals contaminated with HIV changes somewhere in the range of 10% and 80%. Nonstop clinical progressions are giving a noteworthy lift to the development of the market.

Endorsement of novel medications in key locales, for example, North America is relied upon to drive the development of HIV-Associated Lipodystrophy Market. Europe is relied upon to be the second biggest market in HIV-related lipodystrophy market because of high commonness of HIV in Europe.

Most of the noticeable players in the global HIV associated lipodystrophy syndrome are emptying assets into the innovative work of successful therapeutics with the end goal to remain significant in the market.

Read Comprehensive Overview of Report @

https://www.tmrresearch.com/hiv-associated-lipodystrophy-syndrome-market

Noticeable vendors operating in the global HIV associated lipodystrophy syndrome market are Amylin Pharmaceuticals Inc., Amgen Inc., AstraZeneca Plc., Bristol-Myers Squibb Company, and Gilead Sciences Inc., among a few others.

HIV Associated Lipodystrophy Syndrome Market is Expected to be the Fastest Growing Region During 2017 – 2025

Global HIV Associated Lipodystrophy Syndrome Market: Snapshot 

HIV-associated lipodystrophy is a syndrome that are found in human immune-deficiency virus (HIV)-infected patients who are being administered with active antiretroviral medications for the treatment of HIV infection. Patients have lipohypertrophy, an abnormal central fat accumulation or lipoatrophy, localized loss of fat tissue, or a mixed clinical presentations representing both. The complex morphological signs associated with lipodystrophy syndrome inhibits our understanding of the etiology of the disease, and offers significant challenges to clinicians and researchers finding its cure. In addition, the marked difficulty in diagnosing the syndrome is attributed to the subjectivity of symptoms shown making the confirmation difficult through the usual anthropometric measurements and radiological examination.  A concurrent evaluation of multiple parameters is necessary in diagnosing the occurrence of HIV-associated lipodystrophy. Key parameters include clinical, biological, radiological, and demographic. The risk factors associated with the disease is high for patients with age over 40 years and among females. Furthermore, patients with advanced stage of HIV infection are more prone to developing lipodystrophy.

Request Sample Copy of the Report @ https://www.tmrresearch.com/sample/sample?flag=B&rep_id=96

The type of antiretroviral therapy administered and the duration of treatments are the key factors governing the development of HIV-associated lipodystrophy. The introduction of nucleoside reverse transcriptase inhibitor (NRTI) and protease inhibitors (PIs) have independent influence on the development of the symptoms. Currently, there is paucity of effective curative treatments for various morphological changes induced by HIV-associated lipodystrophy and an absence of evidence-based strategies in combating the diseases. Prominent treatment modality including recommending adequate exercise including various a cardiovascular training and strengthening exercise, better nutrition, and minimizing drug exposure. Numerous specific drugs and cosmetic treatments are in the market having varying degrees of success. Efforts to reduce the incidence and prevalence rate of the diseases must focus on developing objective parameters in identifying morphological changes. Innovations in antiretroviral treatment show great promise for companies engaged in finding the cure for the disease.

Request TOC of the Report @ https://www.tmrresearch.com/sample/sample?flag=T&rep_id=96

Global HIV Associated Lipodystrophy Syndrome Market: Overview

Human Immuno-deficiency Virus (HIV) presents itself as a complex mix of symptoms, which are related to severe immune compromise. Lipodystrophy is a condition, commonly associated with HIV patients globally, wherein there is a considerable loss of subcutaneous fat through the body. The increasing prevalence of lipodystrophy is the foremost factor driving the global market for HIV associated lipodystrophy syndrome. Continuous clinical advancements are providing a significant boost to the growth of the market.

This research report provides a comprehensive overview of the current and foreseeable scenario of the global HIV associated lipodystrophy syndrome market. It offers insights into the data pertaining to the clinical trials on HIV associated lipodystrophy syndrome. Primary and secondary research have come into play while collating this study. The information provided in the report has been taken from various paid and unpaid sources including journals, presentations, and white papers. The report presents a detailed description of the dynamics and competitive landscape of the global HIV associated lipodystrophy syndrome market.

Read Comprehensive Overview of Report@ https://www.tmrresearch.com/hiv-associated-lipodystrophy-syndrome-market

Global HIV Associated Lipodystrophy Syndrome Market: Trends and Opportunities

At present, the most widely adopted treatment involves dietary modifications and symptomatic relief of conditions presented. Despite the high effectivity of therapeutic treatment, its adoption is limited by its high cost. Moreover, it demands constant supply of energy compounds (sugar/fat) for patients to maintain a standard daily requirement which is difficult for patients with low income.

It is estimated that the majority of the HIV infected population is living in poor countries, particularly the sub-Saharan Africa region. The low affordability of drugs in such regions is prompting healthcare companies worldwide to provide low-cost drugs so that they can introduce their products to generic competition. Moreover, with the entry of Asian players the prices are bound to decline, thereby driving the adoption of therapeutics for HIV associated lipodystrophy syndrome.

Global HIV Associated Lipodystrophy Syndrome Market: Geographical Segmentation

The key regions methodically examined in the report are North America, Asia Pacific, Europe, and Rest of the World. North America and Europe are likely to represent a substantial combined share in the market throughout the forecast period. The high affordability of drugs in these regions are working in favor of the growth of the market. The improving healthcare infrastructure and rapidly growing population are making Asia Pacific a potentially large market. On the other hand, the unavailability of affordable drugs is restricting the market in this region from realizing its utmost potential. The Rest of the World region is anticipated to follow a similar growth pattern as Asia Pacific.

Global HIV Associated Lipodystrophy Syndrome Market: Competitive Landscape

The majority of the prominent players in the global HIV associated lipodystrophy syndrome are pouring funds into the research and development of effective therapeutics in order to stay relevant in the market. Some of the key players in the market are Gilead Sciences Inc., Amgen Inc., Abbott Laboratories, AstraZeneca Plc., AbbVie Inc., GlaxoSmithKline Plc., Alfa Wassermann S.P.A, Amylin Pharmaceuticals Inc., Theratechnologies Inc., and Bristol-Myers Squibb Company.

Cry for Low Cost Drugs to Propel Lipodystrophy Syndrome Market

San Francisco, California, July 19, 2017: A new TMR Research report, titled “HIV Associated Lipodystrophy Syndrome Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017 – 2025” studies in detail the global market for a syndrome called HIV associated lipodystrophy. This syndrome is commonly found in patients suffering from human immune-deficiency virus (HIV) who are administered with antiretroviral drugs for treating the HIV infection. The report provides a comprehensive overview of the current and future scenario of the international HIV associated lipodystrophy syndrome market.

Human Immuno-deficiency Virus (HIV) is a disease with a complicated mix of symptoms that severely affect the human immune system. Lipodystrophy is a condition where a HIV infected patient suffers an ample amount of subcutaneous fat loss in their body. The lipodystrophy syndrome exhibits very complex morphological signs that hinder the process of understanding the anatomy of the disease and thus, researchers face significant challenges in finding cure for the syndrome. Patients diagnosed with advanced stage of HIV disease are more susceptible to develop HIV associated lipodystrophy syndrome.

In terms of treatment, currently there is a scarcity of effective medications for the different morphological changes that occur due to HIV associated lipodystrophy. Adequate exercise routine, which include different cardiovascular and strengthening exercises is most commonly recommended. Along with the workout, a planned nutrition diet is also recommended. Such dietary modification therapy has proven effective but its high cost hinders the large scale adoption. The treatment demands constant supply of energy packed foods for patients in order to maintain a standard level of sugar/fats in the body.

The report suggests that majority of HIV affected population exists in the underdeveloped or poor countries particularly in the Saharan-Africa region. Affording high cost treatment thus becomes very hard for people living in these regions. Healthcare companies worldwide are now considering to give out low-cost drugs in these areas. Also, the report suggests the entry of Asia healthcare companies is going to spark more decline in the cost of drugs for treating the HIV associated lipodystrophy syndrome. The market is driven by this growing competition and increasing spread of HIV infected population.

Geographically, North America and Europe are expected to contribute significantly in terms market share. Primary reason for this is the high affordability of patients in these regions. Asia Pacific region is also expected to contribute substantially to the global HIV associated lipodystrophy syndrome market. The rapidly increasing population and improving infrastructure for healthcare make Asia Pacific region a huge potential market. On the flip side, scarcity of affordable drugs is impeding the market to reach its highest potential.

Some of the prominent healthcare corporates in the global HIV associated lipodystrophy syndrome market include Gilead Sciences Inc., Abbott Laboratories, Amylin Pharmaceuticals Inc., Theratechnologies Inc., and Amgen Inc. The report mentions profiles of the aforementioned companies along with several others to provide insights into the market’s competitive landscape. These companies are spending large amount of fund into the research and development of new and effective cure to stay relevant in the global HIV associated lipodystrophy syndrome market.